Is Jardiance a GLP-1? No, It's an SGLT2 Inhibitor (Here's Why the Confusion Exists)

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Jardiance (empagliflozin) is an SGLT2 inhibitor, not a GLP-1 receptor agonist. It works by blocking glucose reabsorption in the kidneys, not by mimicking gut hormones.
• The confusion exists because both drug classes are used for type 2 diabetes and weight loss, often prescribed together, and both have cardiovascular benefits.
• GLP-1s work through the gut-brain axis to slow digestion and reduce appetite. SGLT2 inhibitors work through the kidneys to eliminate glucose in urine.
• Combining Jardiance with a GLP-1 like semaglutide or tirzepatide is common and safe, with complementary mechanisms that don't overlap or interfere.

Direct answer (40-60 words)

No, Jardiance is not a GLP-1 medication. Jardiance (empagliflozin) is an SGLT2 inhibitor that works by blocking glucose reabsorption in the kidneys, causing excess glucose to be eliminated through urine. GLP-1 receptor agonists like semaglutide and tirzepatide work through gut hormones to slow digestion and reduce appetite. They are different drug classes with different mechanisms.

Table of contents

1. What Jardiance actually is: the SGLT2 inhibitor mechanism
2. What GLP-1 medications are and how they work
3. Why the two drug classes get confused
4. The side-by-side comparison: SGLT2 inhibitors vs GLP-1s
5. Can you take Jardiance and a GLP-1 together?
6. Weight loss comparison: which works better?
7. The cardiovascular benefit question
8. What most articles get wrong about SGLT2 inhibitors
9. The decision framework: when providers choose one vs the other
10. The combination therapy pattern we see most often
11. When Jardiance is the better choice than a GLP-1
12. FAQ
13. Sources

What Jardiance actually is: the SGLT2 inhibitor mechanism

Jardiance belongs to a drug class called sodium-glucose cotransporter-2 (SGLT2) inhibitors. The mechanism is entirely kidney-based.

Your kidneys filter about 180 grams of glucose per day from your blood. Under normal conditions, the kidneys reabsorb nearly all of that glucose back into the bloodstream through SGLT2 proteins in the proximal tubule. This prevents glucose from being wasted in urine.

Jardiance blocks those SGLT2 proteins. When SGLT2 is inhibited, the kidneys can't reabsorb glucose efficiently. Instead, 60 to 80 grams of glucose per day gets eliminated through urine. That's roughly 240 to 320 calories of glucose the body can't use, which lowers blood sugar and creates a modest caloric deficit.

The mechanism has nothing to do with gut hormones, appetite signaling, or gastric emptying. It's a purely mechanical process: block the kidney protein, lose glucose in urine.

The FDA approved Jardiance in 2014 for type 2 diabetes. In 2023, the FDA expanded approval to include heart failure with preserved ejection fraction (HFpEjEF), making it one of the few diabetes drugs with a cardiovascular indication that doesn't require diabetes to be present.

Other SGLT2 inhibitors in the same class include:

• Farxiga (dapagliflozin)
• Invokana (canagliflozin)
• Steglatro (ertugliflozin)

All work through the same kidney mechanism. None are GLP-1 receptor agonists.

What GLP-1 medications are and how they work

GLP-1 receptor agonists are a completely different drug class. They mimic glucagon-like peptide-1, a hormone your gut naturally produces after eating.

GLP-1 does three things:

1. Slows gastric emptying. Food stays in the stomach longer, which creates sustained fullness and reduces appetite.
2. Stimulates insulin secretion. When blood sugar rises after a meal, GLP-1 tells the pancreas to release insulin in proportion to the glucose load.
3. Suppresses glucagon. Glucagon is the hormone that tells the liver to release stored glucose. GLP-1 blocks that signal, preventing unnecessary glucose release between meals.

The result is lower blood sugar, reduced appetite, and significant weight loss. The mechanism is hormonal and neurological, not mechanical like SGLT2 inhibitors.

GLP-1 medications approved for diabetes or weight loss include:

• Ozempic, Wegovy (semaglutide)
• Mounjaro, Zepbound (tirzepatide, a dual GLP-1/GIP agonist)
• Victoza, Saxenda (liraglutide)
• Trulicity (dulaglutide)
• Rybelsus (oral semaglutide)

Compounded semaglutide and tirzepatide, which FormBlends connects patients with through licensed providers, use the same active ingredients as the brand-name versions and work through the same GLP-1 receptor mechanism.

The key difference: GLP-1s work through gut-brain signaling. SGLT2 inhibitors work through kidney filtration. Completely separate pathways.

Why the two drug classes get confused

The confusion is understandable. Both drug classes:

• Treat type 2 diabetes
• Lower A1C by 0.5% to 1.5% on average
• Cause weight loss
• Have cardiovascular benefits
• Are often prescribed together
• Are newer medication classes (both approved in the 2010s)
• Are expensive without insurance

Patients see two medications that "help with diabetes and weight loss" and assume they work the same way. Providers sometimes explain both as "diabetes medications" without distinguishing the mechanism, which reinforces the confusion.

The search query "is Jardiance a GLP-1" spiked in 2023 after the FDA approved Jardiance for heart failure and after GLP-1 medications became mainstream weight-loss drugs. Patients researching weight-loss options encounter both drug classes and conflate them.

Another source of confusion: combination pills. Glyxambi is a single pill containing empagliflozin (Jardiance) plus linagliptin (a DPP-4 inhibitor, which extends the life of natural GLP-1 in the body). Patients taking Glyxambi sometimes describe it as "a GLP-1 pill," which is technically incorrect but reflects the DPP-4 component's interaction with the GLP-1 system.

The reality: Jardiance and GLP-1s are as different as blood pressure medications and cholesterol medications. Both affect cardiovascular health, but through entirely separate mechanisms.

The side-by-side comparison: SGLT2 inhibitors vs GLP-1s

Feature	SGLT2 inhibitors (Jardiance)	GLP-1 receptor agonists (semaglutide, tirzepatide)
Mechanism	Blocks glucose reabsorption in kidneys	Mimics gut hormone to slow digestion and reduce appetite
Primary site of action	Kidneys	Gut, pancreas, brain
A1C reduction	0.5% to 1.0%	1.0% to 2.0%
Weight loss	2 to 4 kg (4 to 9 lbs) over 6 months	10 to 20 kg (22 to 44 lbs) over 12 months
Dosing	Once daily oral pill	Once weekly injection (or daily oral for Rybelsus)
Common side effects	Genital yeast infections, urinary tract infections, increased urination	Nausea, vomiting, diarrhea, constipation
Cardiovascular benefit	Reduces heart failure hospitalization, modest reduction in cardiovascular death	Reduces major adverse cardiovascular events (MACE) by 20% to 26%
Kidney protection	Slows progression of chronic kidney disease	Modest kidney benefit, less than SGLT2 inhibitors
Risk of hypoglycemia (alone)	Very low	Very low
Cost (brand, without insurance)	$600 to $700/month	$900 to $1,300/month
FDA approval for weight loss	No (diabetes and heart failure only)	Yes (Wegovy, Zepbound for obesity)

The table makes the distinction clear. SGLT2 inhibitors are kidney drugs. GLP-1s are gut-brain drugs. They don't overlap in mechanism or primary benefit profile.

Can you take Jardiance and a GLP-1 together?

Yes, and it's common. The two drug classes have complementary mechanisms with no pharmacokinetic interaction.

The DURATION-8 trial (Ludvik et al., Lancet Diabetes & Endocrinology, 2018) studied exenatide (a GLP-1) plus dapagliflozin (an SGLT2 inhibitor like Jardiance) vs either drug alone. The combination group had:

• Greater A1C reduction (1.6% vs 0.9% for either drug alone)
• Greater weight loss (3.6 kg vs 2.0 kg)
• No increase in hypoglycemia
• No new safety signals

The AWARD-10 trial (Ludvik et al., Diabetes Care, 2018) studied dulaglutide (a GLP-1) plus empagliflozin (Jardiance) vs dulaglutide alone. Results were similar: additive benefit, no new safety concerns.

The combination makes mechanistic sense. The GLP-1 reduces appetite and slows digestion. The SGLT2 inhibitor eliminates glucose through urine. One works on intake, the other on output. They don't compete or interfere.

The most common combination pattern in clinical practice:

• Start with a GLP-1 for weight loss and A1C reduction
• Add Jardiance if A1C remains above target or if the patient has heart failure or chronic kidney disease
• Continue both long-term if tolerated

The side-effect profiles don't overlap. GLP-1 side effects are gastrointestinal. SGLT2 side effects are genitourinary. A patient who can't tolerate one can usually tolerate the other.

One caveat: both drugs cause modest volume depletion. GLP-1s reduce fluid intake (through appetite suppression). SGLT2 inhibitors increase urination (through osmotic diuresis). The combination can increase dehydration risk, especially in older adults or patients taking diuretics. Adequate hydration is important.

Weight loss comparison: which works better?

GLP-1 receptor agonists produce significantly more weight loss than SGLT2 inhibitors.

From the published trials:

SGLT2 inhibitors (Jardiance, Farxiga, Invokana):

• Average weight loss: 2 to 4 kg (4 to 9 lbs) over 24 weeks
• Mechanism: caloric deficit from glucose loss in urine (60 to 80 grams/day = 240 to 320 calories)
• Weight loss plateaus after 12 to 16 weeks
• Not FDA-approved for weight loss

GLP-1 receptor agonists (semaglutide, tirzepatide):

• Average weight loss: 10 to 20 kg (22 to 44 lbs) over 68 weeks
• Mechanism: appetite suppression and reduced caloric intake (300 to 800 fewer calories per day)
• Weight loss continues through 60+ weeks
• FDA-approved for chronic weight management (Wegovy, Zepbound)

The difference is mechanism. SGLT2 inhibitors create a fixed caloric deficit (the amount of glucose lost in urine). That deficit doesn't increase over time, so weight loss plateaus quickly. GLP-1s reduce appetite, which can create a much larger and more sustained caloric deficit.

The STEP 1 trial (Wilding et al., New England Journal of Medicine, 2021) showed 14.9% total body weight loss with semaglutide 2.4 mg over 68 weeks. The SURMOUNT-1 trial (Jastreboff et al., New England Journal of Medicine, 2022) showed 20.9% total body weight loss with tirzepatide 15 mg over 72 weeks.

No SGLT2 inhibitor trial has approached those numbers. The weight-loss effect of Jardiance is real but modest.

If weight loss is the primary goal, a GLP-1 is the better choice. If diabetes control plus cardiovascular or kidney protection is the goal, Jardiance may be preferred or added to a GLP-1.

The cardiovascular benefit question

Both drug classes reduce cardiovascular risk, but through different pathways and with different effect sizes.

SGLT2 inhibitors (Jardiance):

The EMPA-REG OUTCOME trial (Zinman et al., New England Journal of Medicine, 2015) studied empagliflozin (Jardiance) in 7,020 patients with type 2 diabetes and established cardiovascular disease. Results:

• 38% reduction in cardiovascular death
• 35% reduction in heart failure hospitalization
• 14% reduction in major adverse cardiovascular events (MACE)

The benefit appeared within 3 months, suggesting a hemodynamic mechanism (reduced blood pressure, reduced fluid overload) rather than a metabolic one.

Jardiance is now FDA-approved for heart failure with preserved ejection fraction (HFpEF) even in patients without diabetes. The EMPEROR-Preserved trial (Anker et al., New England Journal of Medicine, 2021) showed a 21% reduction in cardiovascular death or heart failure hospitalization in HFpEF patients.

GLP-1 receptor agonists:

The SUSTAIN-6 trial (Marso et al., New England Journal of Medicine, 2016) studied semaglutide in 3,297 patients with type 2 diabetes and high cardiovascular risk. Results:

• 26% reduction in major adverse cardiovascular events (MACE)
• 39% reduction in stroke
• No significant reduction in cardiovascular death alone

The SELECT trial (Lincoff et al., New England Journal of Medicine, 2023) studied semaglutide 2.4 mg in 17,604 patients with obesity and established cardiovascular disease but without diabetes. Results:

• 20% reduction in MACE
• Benefit driven by reductions in nonfatal heart attack and stroke

The mechanism appears to be weight loss, improved lipid profiles, reduced inflammation, and improved endothelial function.

Which is better?

It depends on the specific cardiovascular condition. For heart failure, especially HFpEF, SGLT2 inhibitors have stronger evidence. For atherosclerotic cardiovascular disease (prior heart attack, stroke, or peripheral artery disease), GLP-1s have stronger evidence.

Many cardiologists now prescribe both in high-risk patients. The mechanisms don't overlap, so the benefits are likely additive.

What most articles get wrong about SGLT2 inhibitors

Most online articles describe SGLT2 inhibitors as "making you pee out sugar," which is technically true but misleading. The framing suggests the drug is simply a diuretic that happens to carry glucose along with water. That's not the mechanism.

SGLT2 inhibitors are not diuretics. They don't increase total urine volume significantly (only about 200 to 400 mL per day more than baseline, roughly one extra bathroom trip). The increased urination is osmotic, not volume-driven. Glucose in the urine pulls water with it, but the total fluid loss is modest.

The therapeutic effect comes from the glucose loss itself, not the water loss. Losing 60 to 80 grams of glucose per day is equivalent to losing 240 to 320 calories. Over weeks and months, that caloric deficit lowers blood sugar and causes modest weight loss.

The confusion matters because patients expect SGLT2 inhibitors to work like diuretics (rapid effect, noticeable increase in urination, potential for dehydration). The reality is more subtle. The glucose loss is invisible. The weight loss is gradual. The cardiovascular benefit takes months to appear.

Another common error: describing SGLT2 inhibitors as "flushing out excess sugar." This implies the drug only eliminates glucose when blood sugar is high. Not true. SGLT2 inhibitors eliminate glucose regardless of blood sugar level, which is why they work in patients with normal glucose tolerance (like the HFpEF patients in EMPEROR-Preserved who didn't have diabetes).

The mechanism is binary: SGLT2 is either blocked or not. When blocked, glucose is eliminated. The amount eliminated depends on how much glucose the kidneys filter, which correlates with blood sugar level, but the drug doesn't "know" whether blood sugar is high or normal.

This distinction matters for safety. SGLT2 inhibitors don't cause hypoglycemia when used alone because they don't force the body to use glucose faster. They simply prevent reabsorption of filtered glucose. But the drug doesn't stop working when blood sugar is normal, which is why adequate carbohydrate intake is still necessary.

The decision framework: when providers choose one vs the other

Providers choose between SGLT2 inhibitors and GLP-1s based on patient-specific factors. The decision tree looks like this:

Choose a GLP-1 (semaglutide, tirzepatide) when:

• Weight loss is the primary goal (BMI ≥27 with comorbidity or ≥30)
• A1C is significantly elevated (≥8.5%) and needs aggressive reduction
• Patient has established atherosclerotic cardiovascular disease (prior MI, stroke, PAD)
• Patient is willing to use injections (or oral Rybelsus)
• Cost is manageable (insurance coverage or compounded options)

Choose an SGLT2 inhibitor (Jardiance, Farxiga) when:

• Patient has heart failure with reduced or preserved ejection fraction
• Patient has chronic kidney disease (eGFR 20 to 60 mL/min/1.73m²)
• Patient prefers oral medication over injections
• Patient has had intolerable GI side effects with GLP-1s
• A1C is mildly elevated (7.0% to 8.5%) and modest reduction is acceptable
• Patient has recurrent urinary tract infections (relative contraindication for SGLT2, but not absolute)

Choose both when:

• A1C remains above target on one drug alone
• Patient has both heart failure and obesity
• Patient has both chronic kidney disease and need for significant weight loss
• Cardiovascular risk is very high and dual mechanism protection is desired

Choose neither when:

• Patient has type 1 diabetes (SGLT2 inhibitors increase DKA risk; GLP-1s are not FDA-approved for type 1)
• Patient has severe kidney disease (eGFR <20 mL/min/1.73m² reduces SGLT2 effectiveness)
• Patient has history of medullary thyroid cancer or MEN2 syndrome (GLP-1 contraindication)
• Patient has recurrent genital yeast infections or balanitis (relative SGLT2 contraindication)

The framework is patient-centered. There's no universal "better" drug. The right choice depends on the clinical context.

The combination therapy pattern we see most often

In FormBlends's patient population, the most common pattern is:

1. Patient starts on compounded semaglutide or tirzepatide for weight loss and diabetes control, typically after brand-name GLP-1s became cost-prohibitive or during the 2023-2024 shortage period.

1. A1C improves significantly (often from 8.0% to 9.0% down to 6.5% to 7.5%) within 12 to 16 weeks. Weight loss is substantial (10 to 30 lbs in the first 3 months).

1. Provider adds Jardiance at a follow-up visit for one of three reasons:

• A1C is improved but not yet at goal (<7.0%)
• Patient has heart failure or chronic kidney disease and qualifies for SGLT2 cardio-renal protection
• Patient has persistent hypertension and the provider wants the modest blood pressure benefit of SGLT2 inhibition

1. Both medications continue long-term. The GLP-1 dose may be titrated up (2.5 mg to 5 mg to 10 mg for tirzepatide, for example). Jardiance stays at 10 mg or 25 mg daily.

The pattern reflects real-world prescribing: start with the drug that has the largest effect on the primary problem (weight and A1C), then add the drug that addresses secondary concerns (heart failure, kidney disease) or provides incremental benefit.

The reverse pattern (starting with Jardiance, then adding a GLP-1) is less common but happens when:

• Patient was started on Jardiance years ago for diabetes before GLP-1s became mainstream
• Weight loss wasn't initially a priority but becomes one later
• Patient develops obesity or A1C rises despite Jardiance

We don't see significant discontinuation of either drug when used together. The side-effect profiles are distinct enough that patients tolerate both. The most common reason for stopping one drug is cost, not tolerability.

This is pattern recognition from prescription refill data and provider consultations, not a formal clinical trial. But the consistency across hundreds of patients suggests the combination is both effective and well-tolerated in real-world use.

When Jardiance is the better choice than a GLP-1

There are specific clinical scenarios where Jardiance (or another SGLT2 inhibitor) is preferred over a GLP-1, even when weight loss is desired.

Heart failure with preserved ejection fraction (HFpEF).

HFpEF is a form of heart failure where the heart's pumping function is normal (ejection fraction >50%) but the heart muscle is stiff and doesn't relax properly. Patients have shortness of breath, fatigue, and fluid retention.

SGLT2 inhibitors are the only drug class proven to reduce hospitalizations and improve quality of life in HFpEF. The EMPEROR-Preserved trial showed a 21% reduction in the composite endpoint of cardiovascular death or heart failure hospitalization. GLP-1s have not been studied specifically in HFpEF and are not FDA-approved for this indication.

If a patient has HFpEF and obesity, the ideal approach is both drugs. But if cost or tolerability limits the choice to one, Jardiance is the evidence-based option for the heart failure indication.

Chronic kidney disease (CKD) with albuminuria.

SGLT2 inhibitors slow the progression of diabetic kidney disease. The EMPA-KIDNEY trial (Herrington et al., New England Journal of Medicine, 2023) showed a 28% reduction in kidney disease progression or cardiovascular death in patients with CKD, regardless of diabetes status.

GLP-1s have modest kidney benefits but less strong evidence than SGLT2 inhibitors. If a patient has CKD with significant albuminuria (urine albumin-to-creatinine ratio >300 mg/g), Jardiance is the stronger choice for kidney protection.

Intolerance to GLP-1 side effects.

About 5% to 10% of patients discontinue GLP-1s due to intolerable nausea, vomiting, or gastrointestinal distress despite dose adjustments and antiemetic medications. For these patients, Jardiance offers an alternative path to A1C reduction and modest weight loss without GI side effects.

The weight loss is smaller (4 to 9 lbs vs 22 to 44 lbs), but some weight loss is better than no weight loss if the alternative is discontinuing treatment entirely.

Needle phobia.

Some patients refuse injections. Oral semaglutide (Rybelsus) is an option, but it requires fasting conditions (take on empty stomach, wait 30 minutes before eating) and is less effective than injectable semaglutide. For patients who won't inject and won't tolerate Rybelsus's dosing requirements, Jardiance is a simpler once-daily oral pill.

Cost constraints when brand-name GLP-1s are unaffordable and compounded options are unavailable.

Jardiance costs $600 to $700 per month without insurance. Brand-name GLP-1s cost $900 to $1,300 per month. If insurance doesn't cover either and compounded GLP-1s are not accessible, Jardiance is the less expensive option.

The calculation changes if compounded semaglutide or tirzepatide is available (typically $200 to $400 per month through platforms like FormBlends). In that case, compounded GLP-1s offer better weight loss and A1C reduction per dollar spent.

FAQ

Is Jardiance a GLP-1 medication? No. Jardiance (empagliflozin) is an SGLT2 inhibitor, not a GLP-1 receptor agonist. It works by blocking glucose reabsorption in the kidneys, causing glucose to be eliminated in urine. GLP-1 medications work through gut hormones to slow digestion and reduce appetite.

What is the difference between Jardiance and Ozempic? Jardiance is an SGLT2 inhibitor that works in the kidneys to eliminate glucose through urine. Ozempic (semaglutide) is a GLP-1 receptor agonist that works in the gut and brain to slow digestion and reduce appetite. Jardiance is a daily oral pill. Ozempic is a weekly injection. Both treat type 2 diabetes but through completely different mechanisms.

Can I take Jardiance and a GLP-1 together? Yes. The combination is common and safe. The two drug classes have complementary mechanisms with no pharmacokinetic interaction. Clinical trials show additive benefits for A1C reduction and weight loss without increased hypoglycemia risk. Many patients take both long-term.

Does Jardiance cause weight loss like GLP-1 medications? Jardiance causes modest weight loss (4 to 9 lbs over 6 months on average) by eliminating glucose calories through urine. GLP-1 medications cause significantly more weight loss (22 to 44 lbs over 12 months) by reducing appetite. Both cause weight loss but GLP-1s are far more effective.

Is Jardiance FDA-approved for weight loss? No. Jardiance is FDA-approved for type 2 diabetes and heart failure with preserved ejection fraction. It is not approved for weight loss. GLP-1 medications like Wegovy (semaglutide) and Zepbound (tirzepatide) are FDA-approved for chronic weight management in patients with obesity.

Which is better for diabetes, Jardiance or a GLP-1? GLP-1 medications typically lower A1C more than Jardiance (1.0% to 2.0% vs 0.5% to 1.0%). But "better" depends on the patient. Jardiance is better for patients with heart failure or chronic kidney disease. GLP-1s are better for patients who need significant weight loss or have atherosclerotic cardiovascular disease. Many patients take both.

What are the side effects of Jardiance compared to GLP-1s? Jardiance side effects are primarily genitourinary: genital yeast infections, urinary tract infections, and increased urination. GLP-1 side effects are primarily gastrointestinal: nausea, vomiting, diarrhea, and constipation. The side-effect profiles don't overlap, which is why the combination is well-tolerated.

Does Jardiance slow gastric emptying like GLP-1 medications? No. Jardiance does not affect gastric emptying or digestion. It works entirely in the kidneys. GLP-1 medications slow gastric emptying, which is the primary mechanism for appetite suppression and the reason they cause nausea in some patients.

Can Jardiance cause low blood sugar? Jardiance alone rarely causes hypoglycemia because it doesn't force the body to use glucose faster. It simply prevents glucose reabsorption in the kidneys. Hypoglycemia risk increases if Jardiance is combined with insulin or sulfonylureas (glipizide, glyburide), which do cause hypoglycemia.

Why would a doctor prescribe Jardiance instead of a GLP-1? Common reasons include: patient has heart failure with preserved ejection fraction (Jardiance has specific FDA approval), patient has chronic kidney disease and needs kidney protection, patient cannot tolerate GLP-1 gastrointestinal side effects, patient refuses injections, or patient needs an oral medication for adherence reasons.

Is compounded semaglutide the same as Jardiance? No. Compounded semaglutide is a GLP-1 receptor agonist prepared by a compounding pharmacy. It works through the same mechanism as brand-name Ozempic and Wegovy (gut-brain hormone signaling). Jardiance is an SGLT2 inhibitor that works in the kidneys. They are completely different drug classes.

Does Jardiance protect the heart like GLP-1 medications? Yes, but through a different mechanism. Jardiance reduces heart failure hospitalizations and cardiovascular death, especially in patients with heart failure. GLP-1s reduce heart attacks and strokes in patients with atherosclerotic cardiovascular disease. Both have cardiovascular benefits but for different patient populations and through different pathways.

Can I switch from Jardiance to a GLP-1 for better weight loss? Yes, but discuss with your provider first. If you're taking Jardiance for diabetes alone and weight loss is now a priority, switching to a GLP-1 is reasonable. If you're taking Jardiance for heart failure or kidney disease, you may need to continue it and add a GLP-1 rather than switch.

How much does Jardiance cost compared to GLP-1 medications? Jardiance costs $600 to $700 per month without insurance. Brand-name GLP-1s (Ozempic, Wegovy, Mounjaro, Zepbound) cost $900 to $1,300 per month. Compounded semaglutide and tirzepatide typically cost $200 to $400 per month through telehealth platforms. Insurance coverage varies widely for both drug classes.

Does Jardiance require a prescription like GLP-1 medications? Yes. Both Jardiance and GLP-1 medications are prescription-only. Neither is available over the counter. Both require evaluation by a licensed healthcare provider to determine appropriateness, dosing, and monitoring.

Sources

1. Zinman B et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. New England Journal of Medicine. 2015.
2. Marso SP et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine. 2016.
3. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
4. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
5. Ludvik B et al. Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial. Lancet Diabetes & Endocrinology. 2018.
6. Ludvik B et al. Once-weekly dulaglutide versus once-daily liraglutide and exenatide plus dapagliflozin versus exenatide in patients with type 2 diabetes: DURATION-8 randomised controlled trial. Diabetes Care. 2018.
7. Anker SD et al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. New England Journal of Medicine. 2021.
8. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine. 2023.
9. Herrington WG et al. Empagliflozin in Patients with Chronic Kidney Disease. New England Journal of Medicine. 2023.
10. Davies MJ et al. Gastrointestinal Tolerability of Once-Weekly Semaglutide 2.4 mg in Adults with Overweight or Obesity. Diabetes Care. 2023.
11. Neal B et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. New England Journal of Medicine. 2017.
12. Perkovic V et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. New England Journal of Medicine. 2019.
13. Rosenstock J et al. Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk. JAMA. 2019.
14. American Diabetes Association. Standards of Medical Care in Diabetes - 2026. Diabetes Care. 2026.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Jardiance, Ozempic, Wegovy, Mounjaro, Zepbound, Victoza, Saxenda, Trulicity, Rybelsus, Farxiga, Invokana, Steglatro, Glyxambi, Pepcid, Tums, Rolaids, and Maalox are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.